Progenics elects new chairman
This article was originally published in Scrip
Progenics Pharmaceuticals (US) has elected board member Peter Crowley as chairman of the board. He replaces Kurt Briner, who is stepping down at the end of his term while remaining as a director. Mr Crowley has more than 20 years' experience in healthcare finance as a senior investment banker; he recently retired from a 23-year career at CIBC World Markets, where he had served head of healthcare investment banking since 1995.